The burns and wounds treatment developer is issuing 5 million shares at $14 each.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at firstname.lastname@example.org.
Burns and wounds treatment developer Mediwound will begin trading on the US Nasdaq market today. Clal Biotechnology Industries Ltd. (TASE: CBI), which holds a controlling 63% stake in Mediwound today notified the Tel Aviv Stock Exchange about the pricing of the IPO.
Credit Suisse Securities LLC, Jefferies, BMO Capital Markets and Oppenheimer & Co. are the underwriters. They will be offered the option to purchase 750, 000 additional regular shares at $14, which can be realized no later than 30 days from the IPO.
MediWound’s shares will begin trading Thursday under the MDWD ticker with the IPO to be completed no later than Tuesday March 25.
Published by Globes [online], Israel business news – www.globes-online.com